

### PERSONAL INFORMATION Renato Bassan

#### WORK EXPERIENCE

---

- 2011- Present **Head of Hematology Dept**  
Ospedale dell'Angelo and Ospedale SS. Giovanni e Paolo, Venezia (Italy)
- 1991- 2011 **Consultant in Haematology**  
Hematology Dept., Ospedali riuniti (Italy)  
Acute leukemia therapy, diagnostics, minimal residual disease, risk-oriented therapy, hematopoietic cell transplantation, innovative treatments and immunotherapy, lymphoma and myeloma, chronic leukemias and myelodysplasia

#### EDUCATION AND TRAINING

---

- 1979- **Medical degree**  
Università degli Studi di Padova, Hematology Dept., Ospedale Civile di Vicenza (Italy) ()
- 1982- **Postgraduation specialisation in Clinical Hematology and Laboratory**  
Università degli Studi di Padova, Hematology Dept., Ospedale Civile di Vicenza (Italy) ()

#### ADDITIONAL INFORMATION

---

##### Expertise Publications

##### Publications

2022

Lymphoblastic Lymphoma: a Concise Review.

T Intermesoli · A Weber · M Leoncin · L Frison · C Skert · R Bassan

Current Oncology Reports 2022; <https://doi.org/10.1007/s11912-021-01168-x>.

2021

Acute undifferentiated/unclassifiable leukemia or disseminated non-hematologic neoplasm? When treatment is the compelling decision.

Frison L, Scattolin AM, Leoncin M, Farina G, Bassan R, et al

J Clin Images Med Case Rep. 2021; 2(6): 1456.

PROGRESS IN THE TREATMENT OF ADULT B-CELL PRECURSOR PHILADELPHIA CHROMOSOME-NEGATIVE ALL: RISK ADAPTED TREATMENTS AND NOVEL IMMUNOTHERAPIES. A.

Rambaldi , C. Pavoni , F. Lussana, M. Tosi, O. Spinelli , S. Chiaretti, R. Foa, R. Bassan. Haematologica 2021;106(s3):192.

Host immune system modulation in Ph+ acute lymphoblastic leukemia patients treated with dasatinib and blinatumomab.

Puzzolo MC, Radice G, Peragine N, de Propriis MS, Mariglia P, Vignetti M, Vitale A, Bassan R, Annunziata M, Gaidano G, Rambaldi A, Chiaretti S, Guarini AR, Foa R.

Blood. 2021 Jul 23;blood.2021011822. doi: 10.1182/blood.2021011822.

Prognostic impact of KMT2A-AFF1-positivity in 926 BCR-ABL1-negative B-lineage Acute Lymphoblastic Leukemia patients treated in GIMEMA clinical trials since 1996.  
Piciocchi A, Messina M, Elia L, Vitale A, Soddu S, Testi AM, Chiaretti S, Mancini M, Albano F, Spadano A, Krampera M, Bonifacio M, Cairoli R, Vetro C, Colella F, Ferrara F, Cimino G, Bassan R, Fazi P, Vignetti M. *Am J Hematol*. 2021 May 28. doi: 10.1002/ajh.26253. Online ahead of print.

Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913.  
Chiaretti S, Messina M, Della Starza I, ... Bassan R, Foa R. *Haematologica*. 2021;106(6):1559-1568. doi: 10.3324/haematol.2020.247973.

MRD-Based Therapeutic Decisions in Genetically Defined Subsets of Adolescents and Young Adult Philadelphia-Negative ALL.  
Tosi M, Spinelli O, Leoncin M, Cavagna R, Pavoni C, Lussana F, Intermesoli T, Frison L, Perali G, Carobolante F, Viero P, Skert C, Rambaldi A, Bassan R. *Cancers (Basel)*. 2021 Apr 27;13(9):2108. doi: 10.3390/cancers13092108.

14q32 rearrangements deregulating BCL11B mark a distinct subgroup of T and myeloid immature acute leukemia.  
Di Giacomo D, La Starza R, Gorello P, Pellanera F, Kalender Atak Z, De Keersmaecker K, Pierini V, Harrison CJ, Arniani S, Moretti M, Testoni N, De Santis G, Roti G, Matteucci C, Bassan R, Vandenberghe P, Aerts S, Cools J, Bornhauser B, Bourquin JP, Piazza R, Mecucci C. *Blood*. 2021 Apr 19;blood.2020010510. doi: 10.1182/blood.2020010510. Epub ahead of print. 2020

Updated risk-oriented strategy for acute lymphoblastic leukemia in adult patients 18-65 years: NILG ALL 10/07.  
Bassan R, Pavoni C, Intermesoli T, Spinelli O, Tosi M, Audisio E, Marmont F, Cattaneo C, Borlenghi E, Cortelazzo S, Cavattoni I, Fumagalli M, Mattei D, Romani C, Cortelezzi A, Fracchiolla N, Ciceri F, Bernardi M, Scattolin AM, Depaoli L, Masciulli A, Oldani E, Rambaldi A. *Blood Cancer J*. 2020 Nov 13;10(11):119. doi: 10.1038/s41408-020-00383-2.

Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults.  
Foa R, Bassan R, Vitale A, Elia L, Piciocchi A, Puzzolo MC, Canichella M, Viero P, Ferrara F, Lunghi M, Fabbiano F, Bonifacio M, Fracchiolla N, Di Bartolomeo P, Mancino A, De Propriis MS, Vignetti M, Guarini A, Rambaldi A, Chiaretti S; GIMEMA Investigators. *N Engl J Med*. 2020 Oct 22;383(17):1613-1623. doi: 10.1056/NEJMoa2016272.

National Italian Delphi panel consensus: which measures are indicated to minimize pegylated-asparaginase associated toxicity during treatment of adult acute lymphoblastic leukemia?  
Lussana F, Minetto P, Ferrara F, Chiaretti S, Specchia G, Bassan R. *BMC Cancer*. 2020 Oct 2;20(1):956. doi: 10.1186/s12885-020-07461-5.

Clinical significance of chromatin-spliceosome acute myeloid leukemia: a report from the Northern Italy Leukemia Group (NILG) randomized trial 02/06.  
Caprioli C, Lussana F, Salmoiraghi S, Cavagna R, Buklijas K, Elidi L, Zanghi P, Michelato A, Delaini F, Oldani E, Intermesoli T, Grassi A, Gianfaldoni G, Mannelli F, Ferrero D, Audisio E, Terruzzi E, De Paoli L, Cattaneo C, Borlenghi E, Cavattoni I, Tajana M, Scattolin AM, Mattei D, Corradini P, Campiotti L, Ciceri F, Bernardi M, Todisco E, Cortelezzi A, Falini B, Pavoni C, Bassan R, Spinelli O, Rambaldi A *Haematologica*. 2020 Aug 27. doi: 10.3324/haematol.2020.252825. Epub ahead of print.

Immature Immunoglobulin Gene Rearrangements Are Recurrent in B Precursor Adult Acute Lymphoblastic Leukemia Carrying TP53 Molecular Alterations.  
Salmoiraghi S, Cavagna R, Guinea Montalvo ML, Ubiali G, Tosi M, Peruta B, Intermesoli T, Oldani E, Salvi A, Pavoni C, Giussani U, Bassan R, Rambaldi A, Spinelli O. *Genes (Basel)*. 2020 Aug 20;11(9):960. doi: 10.3390/genes11090960.

High Throughput Molecular Characterization of Normal Karyotype Acute Myeloid Leukemia in the Context of the Prospective Trial 02/06 of the Northern Italy Leukemia Group (NILG).

Silvia Salmoiraghi, Roberta Cavagna,  
Pamela Zanghi, ..., Renato Bassan, Alessandro Rambaldi and Orietta Spinelli.  
Cancers 2020 Aug 11;12(8):2242. doi:  
10.3390/cancers12082242.

Clinical Characteristics and Outcome of West Nile Virus Infection in Patients with Lymphoid Neoplasms: An Italian Multicentre Study.  
Visentin A, Nasillo V, Marchetti M, Ferrarini I, Paolini R, Sancetta R, Rigolin GM, Cibien F, Riva M, Briani C, Marinello S, Piazza F, Gherlinzoni F, Krampera M, Bassan R, Cuneo A, Luppi M, Semenzato G, Marasca R, Trentin L.  
Hemasphere. 2020 Jun 8;4(3):e395. doi: 10.1097/HS9.0000000000000395. eCollection 2020 Jun.  
Early peripheral blast cell clearance predicts minimal residual disease status and refines disease prognosis in AML.  
Mannelli F, Gianfaldoni G, Bencini S, Piccini M, Cutini I, Bonetti MI, Scappini B, Pancani F, Ponziani V, Chiarini M, Borlenghi E, Bassan R, Rossi G, Bosi A.  
Am J Hematol. 2020 Nov;95(11):1304-1313. doi: 10.1002/ajh.25942.

Capture-based Next-Generation Sequencing improves the identification of Immunoglobulin/T-Cell Receptor clonal markers and gene mutations in adult Acute Lymphoblastic Leukemia patients lacking molecular probes.  
R Cavagna, ML Guinea Montalvo, M Tosi, ..., R Bassan, ... and Orietta Spinelli.  
Cancers 2020, 2020 Jun 9;12(6):1505. doi: 10.3390/cancers12061505..

Practical guidance for the management of acute lymphoblastic leukemia (ALL) in the adolescent and young adult population.  
Carobolante F, Chiaretti S, Skert C, Bassan R.  
Ther Adv Hematol. 2020 Feb 3;11:2040620720903531.

Next Generation Sequencing for BCR-ABL1 Kinase Domain Mutations in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Position Paper  
Soverini S, Albano F, Bassan R et al.  
Cancer Medicine 2020 May;9(9):2960-2970.

Early peripheral clearance of leukemia-associated immunophenotypes in AML: centralized analysis of a randomized trial  
Gianfaldoni G, ..., Bassan R  
Blood Adv. 2020 Jan 28;4(2):301-311.

Blinatumomab versus historic standard-of-care treatment for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukaemia  
N Gokbuget, ..., R Bassan.  
Eur J Haematol 2020 Apr;104(4):299-309. doi: 10.1111/ejh.13375.

Quality of Response in Acute Myeloid Leukemia: The Role of Minimal Residual Disease.  
Maurillo L, Bassan R, Cascavilla N, Ciceri F.  
Cancers (Basel). 2019 Sep 23;11(10). pii: E1417. doi: 10.3390/cancers11101417.

2019

Phase II trial with sequential clofarabine and cyclophosphamide for refractory and relapsed philadelphia-negative adult acute lymphoblastic leukemia. Results of the GIMEMA LAL 1610 protocol.  
Bassan R, Fumagalli M, Chiaretti S, Audisio E, Cascavilla N, Paolini S, Delia M, Cerqui E, Mico C, Fabbiano F, Canichella M, Scattolin AM, Perfetti P, Paoloni F, Iodice M, Vitale A, Della Starza I, Fazi P, Vignetti M, Foa R.  
Leuk Lymphoma. 2019 Dec;60(14):3482-3492.

Treatment and Monitoring of Philadelphia Chromosome-Positive Leukemia Patients: Recent Advances and Remaining Challenges  
S Soverini, R Bassan, T Lion  
J Hematol Oncol. 2019 Apr 23;12(1):39

Randomized trial comparing standard versus sequential high-dose chemotherapy for inducing early CR in adult AML  
R Bassan, T Intermesoli, A Masciulli, et al.  
Blood Adv. 2019 Apr 9;3(7):1103-1117.

A systematic literature review and meta-analysis of minimal residual disease as prognostic indicator in adult B-cell acute lymphoblastic leukemia

R Bassan, M Bruggemann, H-S Radcliffe, et al.  
 Haematologica. 2019;104:2028-2039.  
 Clinician concepts of cure in adult relapsed and refractory Philadelphia-negative B cell precursor acute lymphoblastic leukemia - a Delphi study  
 R Bassan, D Hoelzer, X Thomas et al.  
 Adv Ther. 2019 Apr;36(4):870-879.  
 Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia.  
 Gokbuget N, Dombret H, Giebel S, Bruggemann M, Doubek M, Foa R, Hoelzer D, Kim C, Martinelli G, Parovichnikova E, Rambaldi A, Ribera JM, Schoonen M, Stieglmaier JM, Zugmaier G, Bassan R.  
 Hematology. 2019 Dec;24(1):337-348.

2018  
 New Approaches to the Management of Adult Acute Lymphoblastic Leukemia.  
 Bassan R, Bourquin JP, DeAngelo DJ, Chiaretti S.  
 J Clin Oncol. 2018 Sep 21;JCO2017773648. doi: 10.1200/JCO.2017.77.3648. [Epub ahead of print]  
 Lenalidomide treatment of myelodysplastic syndromes with chromosome 5q deletion: Results from the National Registry of the Italian Drug Agency.  
 Arcioni F, Roncadori A, Di Battista V, Tura S, Covezzoli A, Cundari S, Mecucci C; MORE Study Centres.  
 Eur J Haematol. 2018 Jul;101(1):78-85. doi: 10.1111/ejh.13067. Epub 2018 May 22.

2017  
 Minimal Residual Disease Assessment and Risk-based Therapy in Acute Lymphoblastic Leukemia.  
 Bassan R, Intermesoli T, Scattolin A, et al.  
 Clin Clin Lymphoma Myeloma Leuk. 2017 Jul;17S:S2-S9.  
 Selective liver toxicity and therapeutic progress in acute lymphoblastic leukemia. Bassan R.  
 Lancet Haematol. 2017 Aug;4(8):e346-e347  
 New drugs and allogeneic hematopoietic cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment?  
 Patriarca F, Giaccone L, Onida F, ..., Bassan R, ... , Rambaldi A, Bonifazi F, Bruno B. Expert Opin Biol Ther. 2017 17(7):821  
 CEBPA-double-mutated acute myeloid leukemia displays a unique phenotypic profile: a reliable screening method and insight into biological features.  
 F Mannelli, V Ponziani, S Bencini, ..., R Bassan, et al.  
 Haematologica 2017;102:529.  
 Inclusion and response criteria for clinical trials in relapsed/refractory acute lymphoblastic leukemia and usefulness of historical control trials.  
 N Goekbuget, H Dombret, R Bassan et al.  
 Haematologica 2017;102:e118  
 Leucemia Linfoblastica Acuta: Terapie del Giovane-Adulto e Anziano  
 F Carobolante, AM Scattolin, R Bassan.  
 Seminari di Ematologia Clinica 2017;2:20.  
 Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia.  
 Kantarjian H, Stein A, Gokbuget N, ... , Bassan R, ... Topp MS.  
 N Engl J Med. 2017 Mar 2;376(9):836-847.

2016  
 Burkitt Lymphoma in adolescents and young adults: management challenges.  
 M Dozzo, ..., R Bassan  
 Adolesc Health Med Ther. 2016 Dec 23;8:11-29.  
 Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia.

Gokbuget N, Kelsh M, Chia V, Advani A, Bassan R, et al. Blood  
 Cancer J. 2016 Sep 23;6(9):e473. doi: 10.1038/bcj.2016.84.

International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia.

Gokbuget N, Dombret H, Ribera JM, Fielding AK, Advani A, Bassan R, et al. Haematologica 2016 Dec;101(12):1524-1533.

Achieving a Molecular Remission before Allogeneic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia: Impact on Relapse and Long Term Outcome.

Lussana F, Intermesoli T, Gianni F, ..., Bassan R, Rambaldi A.  
 Biol Blood Marrow Transplant. 2016 Nov;22(11):1983-1987.

Reply to C.S. Hourigan et al.  
 Bassan R.  
 J Clin Oncol. 2016 Jul 20;34(21):2559-60.

Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL.

Rousselot P, Coude MM, Gokbuget N, ... Bassan R, Delord M, Hoelzer D, Dombret H, Ottmann OG.  
 Blood. 2016 Aug 11;128(6):774-82.

Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Hoelzer D, Bassan R, Dombret H, Fielding A, Ribera JM, Buske C; ESMO Guidelines Committee.  
 Ann Oncol. 2016 Sep;27(suppl 5):v69-v82.

Immunotherapy approaches to treat adult acute lymphoblastic leukemia.

Maino E, Bonifacio M, Scattolin AM, Bassan R.  
 Expert Rev Hematol. 2016 Jun;9(6):563-77.

Mutations of TP53 in adult acute lymphoblastic leukemia at diagnosis do not affect the achievement of hematologic response but correlate with early relapse and very poor survival.

Salmoiraghi S, Guinea Montalvo ML, Ubiali G, Tosi M, Peruta B, Zanghi P, Oldani E, Boschini C, Kohlmann A, Bungaro S, Intermesoli T, Terruzzi E, Angelucci E, Cavattoni I, Ciceri F, Bassan R, Rambaldi A, Spinelli O.  
 Haematologica. 2016 Jun;101(6):e245-8.

Using Minimal Residual Disease to Improve Treatment Response Definitions and Hematopoietic Cell Transplantation Strategy in Acute Leukemia.  
 Bassan R.  
 J Clin Oncol. 2016 Feb 1;34(4):300-2.

Lymphoblastic lymphoma: an updated review on biology, diagnosis and treatment.  
 Bassan R, Maino E, Cortelazzo S.  
 Eur J Haematol. 2016 May;96(5):447-60.

2015

Bassan R, Spinelli O.  
 Minimal Residual Disease Monitoring in Adult ALL to Determine Therapy.  
 Curr Hematol Malig Rep. 2015 Jun;10(2):86-95.

Bassan R, Masciulli A, Intermesoli T, Audisio E, Rossi G, Pogliani EM, Cassibba V, Mattei D, Romani C, Cortelezzi A, Corti C, Scattolin AM, Spinelli O, Tosi M, Parolini M, Marmont F, Borlenghi E, Fumagalli M, Cortelazzo S, Gallamini A, Marfisi RM, Oldani E, and Rambaldi A.  
 Randomized trial of radiation-free central nervous system prophylaxis comparing intrathecal triple therapy with liposomal cytarabine in acute lymphoblastic leukemia.  
 Haematologica. 2015 Jun;100(6):786-93.

Piccin A, Steurer M, Mitterer M, Blochl EM, Marcheselli L, Pusceddu I, Marabese A, Bertozzi I, Corvetta D, Randi ML, Elli E, Pogliani EM, Veneri D, Perbellini O, Krampera M, Pacquola E, Gottardi M, Tiribelli M, Guella A, Innella B, Vivaldi P, De Biasi E, Sancetta R, Rocconi R, Bassan R, Gherlinzoni F, Pizzolo G, Gastl G, Cortelazzo S.

Role of blood cells dynamism on hemostatic complications in low-risk patients with essential thrombocythemia.

Intern Emerg Med. 2015 Jun;10(4):451-60.

Maino E, Scattolin AM, Viero P, Sancetta R, Pascarella A, Vespignani M, Bassan R.

Modern immunotherapy of adult B-lineage acute lymphoblastic leukemia with monoclonal antibodies and chimeric antigen receptor modified T cells.

Mediterr J Hematol Infect Dis. 2015 Jan 1;7(1):e2015001. doi: 10.4084/MJHID.2015.001. eCollection 2015. Review.PMID:25574360

2014

Orietta Spinelli, Manuela Tosi, Marie Lorena Guinea Montalvo, Barbara Peruta, Margherita Parolini, Anna Maria Scattolin, Elena Maino, Piera Viero, Alessandro Rambaldi & Renato Bassan.

Prognostic impact of minimal

residual disease in adult acute lymphoblastic leukemia.

Int. J. Hematol. Oncol. (2014)

3(6), 419-431

Chiaretti S, Zini G, Bassan R. Diagnosis and subclassification of acute lymphoblastic leukemia.

Mediterr J Hematol Infect Dis. 2014 Nov 1;6(1):e2014073. doi: 10.4084/MJHID.2014.073.

eCollection 2014. Review.PMID: 25408859

Rohatiner AZ, Smith ML, Spinelli O, Rambaldi A, Bassan R, di Bona E, Rodeghiero F, Raimondi R, Bjorkholm M, Johnson S, Newland AC, Cavenagh JD, Macdougall F, Waters R, Fitzgibbon J, Barbui T, Lister A. Myeloblastic therapy with autologous haematopoietic stem cell support as consolidation of first remission in acute myeloid leukaemia - very long follow-up. Br J Haematol. 2014 Jul 29. doi: 10.1111/bjh.13055. [Epub ahead of print]

Spinelli O, Tosi M, Peruta B, Montalvo ML, Maino E, Scattolin AM, Parolini M, Viero P, Rambaldi A, Bassan R. Prognostic significance and treatment implications of minimal residual disease studies in Philadelphia-negative adult acute lymphoblastic leukemia.

Mediterr J Hematol Infect Dis. 2014 Sep 1;6(1):e2014062. doi: 10.4084/MJHID.2014.062.

eCollection 2014. Review.

Bassan R et al. Different molecular levels of post-induction minimal residual disease may predict hematopoietic stem cell transplantation outcome in adult Philadelphia-negative acute lymphoblastic leukemia. Blood Cancer J. 2014 Jul 11;4:e225. doi: 10.1038/bcj.2014.48.

Bassan R. Minimal Residual Disease (MRD) Study to Optimize Definition and Therapy of High-Risk Acute Lymphoblastic Leukemia [Podcast]. J Clin Oncol April 21, 2014 JCO.2013.52.2425

Maino E, Sancetta R, Viero P, Imbergamo S, Scattolin AM, Vespignani M, Bassan R.

Current and future management of Ph/BCR-ABL positive ALL. Expert Rev Anticancer Ther. 2014 Mar 10; 1-18.

Bassan R. Ph+ ALL: imatinib grows older with patients. Blood. 2014 Feb 6;123(6):801-3. doi: 10.1182/blood-2013-12-542423.

Parolini M, Mecucci C, Matteucci C, Giussani U, Intermesoli T, Tosi M, Rambaldi A, Bassan R. Highly aggressive T-cell acute lymphoblastic leukemia with t(8;14)(q24;q11): extensive genetic characterization and achievement of early molecular remission and long-term survival in an adult patient. Blood Cancer J. 2014 Jan 17;4:e176. doi: 10.1038/bcj.2013.72.

2013

Scattolin AM, .... Bassan R. Addressing unmet needs in ALL management. Hospital Oncology & Haematology Europe, Autumn 2013: 30-33.

Bassan R et al. Monoclonal antibody therapy of adult acute lymphoblastic leukemia: progress and challenge for new clinical trials. Drugs and Cell Therapies in Hematology 2013;1:5-20.

Bassan R. Current and future management of Ph/BCR-ABL positive ALL. Proceedings 4th International Congress on Leukemia Lymphoma Myeloma 2013 (Istanbul, Turkey), 89-93.

Intermesoli T, Rambaldi A, Rossi G, Delaini F, Romani C, Pogliani EM, Pagani C, Angelucci E, Terruzzi E, Levis A, Cassibba V, Mattei D, Gianfaldoni G, Scattolin AM, Di Bona E, Oldani E, Parolini M, Gokbuget N, Bassan R. High cure rates in Burkitt lymphoma and leukemia: NILG study of the German short intensive rituximab-chemotherapy program.

Haematologica. 2013 Jun 10. [Epub ahead of print] PMID: 23753030.

2012

Bassan R. Toward victory in adult ALL: blinatumomab joins in. Blood. 2012 Dec 20;120(26):5094-5. doi: 10.1182/blood-2012-10-460394.

Gupta V, Richards S, Rowe J; Acute Leukemia Stem Cell Transplantation Trialists' Collaborative Group. Allogeneic, but not autologous, hematopoietic cell transplantation improves survival only among younger adults with acute lymphoblastic leukemia in first remission: an individual patient data meta-analysis. *Blood*. 2013 Jan 10;121(2):339-50. doi: 10.1182/blood-2012-07-445098. Epub 2012 Nov 19.

Bassan R et al. Modern therapy of young and adult Ph- ALL. *Leukemia* 2012 (supplement 2);1, S5-S6.

Bassan R. Novel approaches for therapy of resistant acute lymphoblastic leukemia. *Hematology Education*, 2012, pp. 9-21.

Mannelli F, Gianfaldoni G, Intermesoli T, Cattaneo C, Borlenghi E, Cortelazzo S, Cavattoni I, Pogliani EM, Fumagalli M, Angelucci E, Romani C, Ciceri F, Corti C, Scattolin A, Cortelezzi A, Mattei D, Audisio E, Spinelli O, Oldani E, Bosi A, Rambaldi A, Bassan R.

CD20 expression has no prognostic role in Philadelphia-negative B-precursor acute lymphoblastic leukemia: new insights from the molecular study of minimal residual disease.

*Haematologica*. 2012 Apr;97(4):568-71. Epub 2011 Nov 4

Intermesoli T, Castagnetti F, Soverini S, Bussini A, Spinelli O, Gnani A, Bassan R, Rosti G.

Durable molecular response despite F317L and E255K mutations: Successful treatment of chronic myeloid leukemia with sequential imatinib, nilotinib and dasatinib.

*Leuk*

*Res*. 2012 Jan;36(1):e10-1. Epub 2011 Oct 1.

Cortelazzo S, Intermesoli T, Oldani E, Ciceri F, Rossi G, Pogliani EM, Mattei D, Romani C, Cortelezzi A, Borlenghi E, Corti C, Peruta B, Spinelli O, Rambaldi A, Bassan R.

Results of a lymphoblastic leukemia-like chemotherapy program with risk-adapted mediastinal irradiation and stem cell transplantation for adult patients with lymphoblastic lymphoma. *Ann Hematol*. 2012 Jan;91(1):73-82. Epub 2011 May 11.

2011

Grossmann V, Tiacci E, Holmes AB, Kohlmann A, Martelli MP, Kern W, Spanhol-Rosseto A, Klein HU, Dugas M, Schindela S, Trifonov V, Schnittger S, Haferlach C, Bassan R, Wells VA, Spinelli O, Chan J, Rossi R, Baldoni S, De Carolis L, Goetze K, Serve H, Peceny R, Kreuzer KA, Oruzio D, Specchia G, Di Raimondo F, Fabbiano F, Sborgia M, Liso A, Farinelli L, Rambaldi A, Pasqualucci L, Rabadan R, Haferlach T, Falini B.

Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype. *Blood*. 2011 Dec 1;118(23):6153-63. Epub 2011 Oct 19.

Bassan R. Optimal central nervous system prophylaxis in Philadelphia chromosome-positive acute lymphoblastic leukemia: collateral damage in the imatinib era?

*Leuk Lymphoma*. 2011

Jul;52(7):1164-5. Epub 2011 May 25.

Bassan R, Intermesoli T, Oldani E, Spinelli O, Rambaldi A.

Acute lymphoblastic leukemia in the elderly. *Haematologica*. 2011;96 (s3): 234-236.

Bassan R, Oldani E, Intermesoli T. Prognostic factors and risk-adapted therapy. The European Working Group on Adult ALL (EWALL): Adult acute lymphoblastic leukemia. 2011, UNI-MED Verlag AG, Bremen-London-Boston, pp.65-73.

Bassan R, Intermesoli T. Induction therapy. The European Working Group on Adult ALL (EWALL): Adult acute lymphoblastic leukemia. 2011, UNI-MED Verlag AG, Bremen-London-Boston, pp.40-52.

Bassan R, Intermesoli T. Consolidation therapy. The European Working Group on Adult ALL (EWALL): Adult acute lymphoblastic leukemia. 2011, UNI-MED Verlag AG, Bremen-London-Boston, pp.73-79.

Hehlmann R, Grimwade D, Simonsson B, Apperley J, Baccarani M, Barbui T, Barosi G, Bassan R et al. The European LeukemiaNet. Achievements and perspectives.



Bassan R, Hoelzer D. Review Series (Leukemia): Modern Therapy of Acute Lymphocytic Leukemia. J Clin Oncol. 2011 Feb 10;29(5):532-43. Epub 2011 Jan 10. Review.

Goekbuget N, Hartog N, Bassan R et al. Liposomal cytarabine is effective and tolerable in the treatment of CNS relapse of acute lymphoblastic leukemia (ALL) and very aggressive lymphoma. Haematologica. 2011 Feb;96(2):238-44. Epub 2010 Oct 15.

#### 2010

Bassan R, Rossi G, Pogliani EM, Di Bona E, Angelucci E, Cavattoni I, Lambertenghi-Deliliers G, Mannelli F, Levis A, Ciceri F, Mattei D, Borlenghi E, Terruzzi E, Borghero C, Romani C, Spinelli O, Tosi M, Oldani E, Intermesoli T, Rambaldi A. Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00. J Clin Oncol. 2010 Aug 1;28(22):3644-52. Epub 2010 Jul 6.

Bruggemann M, Schrauder A, Raff T, Pfeifer H, Dworzak M, Ottmann OG, Asnafi V, Baruchel A, Bassan R, et al. Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia. 2010 Mar;24(3):521-35. Epub 2009 Dec 24.

Bassan R, Intermesoli T. Leucemia linfoblastica acuta. Seminari di Ematologia Oncologica 2010; 7: 39.

#### 2009

Intermesoli T, Delaini F, Acerboni S, Salmoiraghi S, Spinelli O, Guerini V, Vannucchi AM, Mappa S, Rossi G, Rossi V, Di Bona E, Paratore S, Carobbio A, Rambaldi A, Barbui T, Bassan R. A short low-dose imatinib trial allows rapid identification of responsive patients in hypereosinophilic syndromes. Br J Haematol. 2009 Dec;147(5):681-5. Epub 2009 Sep 4.

Bassan R, Spinelli O, Oldani E, Intermesoli T, Tosi M, Peruta B, Rossi G, Borlenghi E, Pogliani EM, Terruzzi E, Fabris P, Cassibba V, Lambertenghi-Deliliers G, Cortelezzi A, Bosi A, Gianfaldoni G, Ciceri F, Bernardi M, Gallamini A, Mattei D, Di Bona E, Romani C, Scattolin AM, Barbui T, Rambaldi A. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood. 2009 Apr 30;113(18):4153-62. Epub 2009 Jan 13.

#### 2007

Intermesoli T, Mangili G, Salvi A, Biondi A, Bassan R. Abnormally expanded pro-B hematogones associated with congenital cytomegalovirus infection. Am J Hematol. 2007 Oct;82(10):934-6.

Mattei D, Bassan R, Mordini N, Rapezzi D, Rambaldi A, Strola G, Peretti C, Del Grosso F, Ferraris AM, Castellino C, Gallamini A. Expansion of B cell precursors after unrelated cord blood transplantation for an adult patient. Bone Marrow Transplant. 2007 Aug;40(3):283-5.

Spinelli O, B Peruta, M Tosi, V Guerini, A Salvi, MC Zanotti, E Oldani, A Grassi, T Intermesoli, C Mico, G Rossi, P Fabris, G Lambertenghi-Deliliers, E Angelucci, T Barbui, Bassan R, A Rambaldi. Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high risk acute lymphoblastic leukemia. Haematologica/Hematol J 2007; 92: 612.

#### 2006

Iacobucci I, Saglio G, Rosti G, Testoni N, Pane F, Amabile M, Poerio A, Soverini S, Bassi S, Cilloni D, Bassan R, Breccia M, Lauria F, Izzo B, Merante S, Frassoni F, Paolini S, Montefusco E, Baccarani M, Martinelli G; GIMEMA Working Party on Chronic Myeloid Leukemia. Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. Clin Cancer Res. 2006 May 15;12(10):3037-42.

Golay J, Cortiana C, Manganini M, Cazzaniga G, Salvi A, Spinelli O, Bassan R, Barbui T, Biondi A, Rambaldi A, Introna M. The sensitivity of acute lymphoblastic leukemia cells carrying the t(12;21) translocation to campath-1H-mediated cell lysis. Haematologica. 2006 Mar;91(3):322-30.

#### 2005

Di Bona E, Pogliani E, Rossi G, Lerede T, D'Emilio A, Vespignani M, Rodeghiero F, Barbui T, Bassan R. Transplant-finalized salvage of adult acute lymphoblastic leukemia: results of a mitoxantrone- and methotrexate-based regimen in 36 patients.

Leuk Lymphoma. 2005 Jun;46(6):879-84.



Bassan R, T Intermesoli, T Barbui. Leucemia acuta linfoblastica nell'anziano. *Oncology & Hematology*, Anno 6, N°III, Settembre 2005

Bassan R.  
Evolving strategies for the management of high-risk adult acute lymphoblastic leukemia. *Haematologica* 2005; 90: 1299.

Locati F, Parma A, Bassan R et al. Malattia da trapianto contro l'ospite. *Incontri Dermatologici* 2005; 9: 28.

2004

Bassan R.  
The value of allogeneic stem cell transplantation in adult acute lymphoblastic leukemia. *Haematologica* 2004; 89(7):770.

Gokbuget N, Bassan R, Dekker A, Dombret H, Foa R, Ifrah N, Kovacsovics T, Labar B, Mandelli F, Meloni G, Ribera JM, Smedmyr B, Vernant JP, Walewski J, Willemze R, Hoelzer D; European Working Group for Adults ALL (EWALL). Developing a European network for adult ALL. *Hematol J*. 2004;5 Suppl 3:S46-52.

Bassan R, Gatta G, Tondini C, Willemze R. Adult acute lymphoblastic leukaemia. *Crit Rev Oncol Hematol*. 2004 Jun;50(3):223-61. Review.

Smith M, Barnett M, Bassan R, Gatta G, Tondini C, Kern W. Adult acute myeloid leukaemia. *Crit Rev Oncol Hematol*. 2004 Jun;50(3):197-222. Review.

Bassan R, Locatelli G, Borleri G, Salvi A, Barbui T.  
Immunophenotypic evaluation of circulating T-cell clones in hypereosinophilic syndromes with or without abnormal CD3 and CD4 lymphocytes. *Haematologica*. 2004 Feb;89(2):238-9.

Bassan R, T Barbui. Fattori di crescita granulocitaria nella terapia intensiva ematologica e nel trapianto di cellule staminali. *Attualita in tema di neutropenia in oncoematologia*. *EdiSES* 2004; 87.

2003

Bassan R.  
L'ABC delle leucemie acute. *Ematologia Pratica* 2003; 1: 5-17.

Bassan R, Spinelli O, Rambaldi A, Barbui T. The course of monoclonal 'villous' lymphocytosis over 15 years of follow-up: progression to SLVL or spontaneous clinical but not molecular remission. *Leukemia*. 2003 Nov;17(11):2243-4.

Scrideli CA, Cazzaniga G, Fazio G, Pirola L, Callegaro A, Bassan R, Rambaldi A, Lo Nigro L, Basso G, Masera G, Biondi A. Gene expression profile unravels significant differences between childhood and adult Ph+ acute lymphoblastic leukemia. *Leukemia*. 2003 Nov;17(11):2234-7.

Bassan R et al. Limited success with a postremission strategy comprising conventional consolidation and high-dose treatment (HDT) with autologous peripheral progenitor cell (PBPC) support for adult acute lymphoblastic leukemia. *Acute Leukemias IX* (eds. W Hiddemann et al.), *Haematol Bloodtransfus*, Springer Verlag 2003, 41: 451.

Di Bona E, ..., Bassan R. Salvage therapy for resistant or relapsing acute lymphoblastic leukemia (ALL) after idarubicin-based induction. *Acute Leukemias IX* (eds. W Hiddemann et al.), *Haematol Bloodtransfus*, Springer Verlag 2003, 41: 461.

2002

Bassan R.  
Management of infections in patients with leukemia. *LEUKEMIA* (7th edition). Ed: ES Henderson, TA Lister, MF Greaves. Saunders 2002, p 297.

Petit B, Mele L, Rack K, Camera A, Vekemans MC, Bassan R, Pulsoni A, Delannoy A, Pagano L. Characteristics of secondary acute lymphoblastic leukemia with L3 morphology in adult patients. *Leuk Lymphoma*. 2002 Aug;43(8):1599-604.

Bassan R, Chiodini B, Lerede T, Giussani U, Oldani E, Buelli M, Rossi A Viero P, Rambaldi A, Barbui T. Prolonged administration of all-trans retinoic acid in combination with intensive chemotherapy and G-CSF for adult acute myelogenous leukemia: single-centre pilot study in different risk groups. *Hematol J*. 2002;3(4):193-200.

Bassan R, Reseghetti A, Cortelazzo S, Rossi A, Buelli M, Viero P, Barbui T. Gigantic cutaneous lymphoma following Di Bella's therapy. *Haematologica*. 2002 Apr;87(4):E1M13.

Bassan R, Lerede T, Borleri G, Chiodini B, Rossi A, Buelli M, Rambaldi A, Viero P, Barbui T.

Phase I trial with escalating doses of idarubicin and multidrug resistance reversal by short-course cyclosporin A, sequential high-dose cytosine arabinoside, and granulocyte colony-stimulating factor for adult patients with refractory acute leukemia.

Haematologica. 2002 Mar;87(3):257-63.

Bassan R. Leucemia acuta dell'adulto: come identificare i pazienti da avviare al trapianto allogenico di cellule staminali emopoietiche. Atti 1° corso Trapianto di cellule staminali allogeniche, Milano, 2002, p. 11.

2001

Di Gaetano N, Xiao Y, Erba E, Bassan R, Rambaldi A, Golay J, Introna M. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br J Haematol. 2001 Sep;114(4):800-9.

Bassan R, Pogliani E, Casula P, Rossi G, Fabris P, Morandi S, Lambertenghi-Deliliers G, Vespignani M, Lerede T, Rambaldi A, Borleri G, Spedini P, Cortelezzi A, Izzi T, Coser P, Brocchia G, Corneo G, Barbui T. Risk-oriented postremission strategies in adult acute lymphoblastic leukemia: prospective confirmation of anthracycline activity in standard-risk class and role of hematopoietic stem cell transplants in high-risk groups.

Hematol J. 2001;2(2):117-26.

Bassan R et al. Early application of anthracyclines in adult acute lymphoblastic leukemia (ALL). Acute Leukemias VIII, ed. Buchner T. et al., Springer Verlag, Berlin, 2001, p. 402.

Bassan R et al. Preliminary results of a risk-oriented program for B-lineage adult acute lymphoblastic leukemia (ALL): the collaborative italian study 08/96.

Acute Leukemias VIII, ed. Buchner T. et al., Springer Verlag, Berlin, 2001, p. 419.

Bassan R et al. Prognostic factors in Philadelphia+/BCR-ABL+ acute lymphoblastic leukemia. Acute Leukemias VIII, ed. Buchner T. et al., Springer Verlag, Berlin, 2001, p. 426.

Bassan R et al. Split-course high-dose ARA-C plus idarubicin and multidrug blockade by short cyclosporin-A infusion for refractory acute myeloid leukemia.

Acute Leukemias VIII, ed. Buchner T. et al., Springer Verlag, Berlin, 2001, p. 438.

Bassan R. Ruolo dei fattori di crescita ematopoietici: uso, indicazioni e limiti di G- e GM-CSF nei pazienti con leucemia acuta. Relazioni SIE 2001, Scientific Press: 65-73.

2000

Rohatiner AZ, Bassan R, Raimondi R, Amess JA, Arnott S, Personeni A, Rodeghiero F, Barbui T, Bradburn MJ, Carter M, Lister TA. High-dose treatment with autologous bone marrow support as consolidation of first remission in younger patients with acute myelogenous leukaemia. Ann Oncol. 2000 Aug;11(8):1007-15.

Bassan R et al. Possible prognostic benefit from ABMT in first remission adult acute lymphoblastic leukemia. Transplantation in Hematology and Oncology, ed. Buchner et al., Springer Verlag, Berlin, 2000, p. 217.

Bassan R et al. Updated results of an age-adapted consolidation strategy with ABMT (<50 years) or high-dose Ara-C (HiDAC, >50 years) in adult acute myeloid leukemia.

Transplantation in Hematology and Oncology, ed. Buchner et al., Springer Verlag, Berlin, 2000, p. 226.

Bassan R, Rohatiner AZ, Lerede T, Di Bona E, Rambaldi A, Pogliani E, Rossi G, Fabris P, Morandi S, Casula P, Carter M, Lambertenghi-Deliliers G, Lister TA, Barbui T.

Role of early anthracycline dose-intensity according to expression of Philadelphia chromosome/BCR-ABL rearrangements in B-precursor adult acute lymphoblastic leukemia.

Hematol J. 2000;1(4):226-34.

Bassan R.

Proposte di linee guida nell'uso dei fattori di crescita emopoietici. In: Linee guida di terapia antibiotica in onco-ematologia, CIC Edizioni Internazionali 2000; 109-19.

1999

Bassan R, Pogliani E, Lerede T, Fabris P, Rossi G, Morandi S, Casula P, Lambertenghi-Deliliers G, Vespignani M, Izzi T, Coser P, Corneo G, Barbui T. Fractionated cyclophosphamide added to the IVAP regimen (idarubicin-vincristine-L-asparaginase-prednisone) could lower the risk of primary refractory disease in T-lineage but not B-lineage acute lymphoblastic leukemia: first results from a phase II clinical study.

Haematologica. 1999 Dec;84(12):1088-93.

Pagano L, Pulsoni A, Tosti ME, Annino L, Mele A, Camera A, Martino B, Guglielmi C, Cerri R, Di Bona E, Invernizzi R, Castagnola C, Bassan R, Mele L, Todeschini G, Leone G, Mandelli F. Acute lymphoblastic leukaemia occurring as second malignancy: report of the GIMEMA archive of adult acute leukaemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. *Br J Haematol.* 1999 Sep;106(4):1037-40.

Bassan R, Rohatiner AZ, Rambaldi A, Lerede T, Di Bona E, Carter M, Rossi G, Pogliani E, Lambertenghi-Deliliers G, Fabris P, Porcellini A, Lister TA, Barbui T. Clinical sensitivity to anthracyclines in PH/BCR+ acute lymphoblastic leukemia. *Adv Exp Med Biol.* 1999;457:489-99.

Chiodini B, Bassan R, Barbui T. Apoptosis by anthracyclines at therapeutic concentrations in MDR1+ human leukemic cells. *Adv Exp Med Biol.* 1999;457:313-24.

Chiodini B, Bassan R, Barbui T. Cellular uptake and antiproliferative effects of therapeutic concentrations of idarubicin or daunorubicin and their alcohol metabolites, with or without cyclosporin A, in MDR1+ human leukemic cells. *Leuk Lymphoma.* 1999 May;33(5-6):485-97.

Bassan R, Lerede T, Di Bona E, Rambaldi A, Rossi G, Pogliani E, Oriani A, D'Emilio A, Izzi T, Lambertenghi-Deliliers G, Corneo G, Barbui T. Induction-consolidation with an idarubicin-containing regimen, unpurged marrow autograft, and post-graft chemotherapy in adult acute lymphoblastic leukaemia. *Br J Haematol.* 1999 Mar;104(4):755-62.

1998

Bassan R, Raimondi R, Lerede T, D'emilio A, Buelli M, Borleri G, Personeni A, Bellavita P, Rodeghiero F, Barbui T. Outcome assessment of age group-specific (+/- 50 years) post-remission consolidation with high-dose cytarabine or bone marrow autograft for adult acute myelogenous leukemia. *Haematologica.* 1998 Jul;83(7):627-35.

Bassan R, Lerede T, Buelli M, Borleri G, Bellavita P, Rambaldi A, Barbui T.

A new combination of carboplatin, high-dose cytarabine and cross-over mitoxantrone or idarubicin for refractory and relapsed acute myeloid leukemia.

*Haematologica.* 1998 May;83(5):422-7.

Bassan R, Chiodini B, Zucchetti M, Lerede T, Cornelli PE, Cortelazzo S, Barbui T.

Short course infusional idarubicin plus intermittent cytarabine and etoposide for refractory hematologic malignancies: clinical and preliminary pharmacological results.

*Haematologica.* 1998 Jan;83(1):27-33.

Bassan R. Randomized clinical trials in adult acute lymphoblastic leukemia: which is the question? *Haematologica.* 1998 Mar;83(3):193-6.

Chiodini B, Bassan R et al. Idarubicin activity against multidrug resistant (mdr-1+) cells is increased by cyclosporin A. *Acute Leukemias VII*, ed. Hiddemann et al., Springer Verlag, Berlin, 1998, p. 475.

Lerede T, Bassan R et al. Prolonged remission in adult B-ALL (L3) and advanced Burkitt's lymphoma using acute leukaemia regimens: study of 34 patients.

*Acute Leukemias VII*, ed. Hiddemann et al., Springer Verlag, Berlin, 1998, p. 783.

Bassan R et al. Carboplatin-based high-dose therapy for refractory acute myeloid leukemia. *Acute Leukemias VII*, ed. Hiddemann et al., Springer Verlag, Berlin, 1998, p. 978.

1997

Bassan R, Chiodini B, Lerede T, Torri V, Borleri G, Rambaldi A, Barbui T.

The role of idarubicin in adult acute lymphoblastic leukaemia: from drug resistance studies to clinical application. *Leuk Lymphoma.* 1997 Dec;26 Suppl 1:89-97.

Bassan R, Lerede T, Di Bona E, Rossi G, Pogliani E, Rambaldi A, Buelli M, Viero P, Rodeghiero F, Izzi T, Corneo G, Barbui T. Granulocyte colony-stimulating factor (G-CSF, filgrastim) after or during an intensive remission induction therapy for adult acute lymphoblastic leukaemia: effects, role of patient pretreatment characteristics, and costs. *Leuk Lymphoma.* 1997 Jun;26(1-2):153-61.

Rossi A, Cortelazzo S, Bellavita P, Viero P, Bassan R, Comotti B, Marchioli R, Marfisi RM, Rambaldi A, Barbui T. Long-term haematological reconstitution following BEAM and autologous transplantation of circulating progenitor cells in non-Hodgkin's lymphoma.

*Br J Haematol.* 1997 Mar;96(3):620-6.

Bassan R et al. Correlation between early anthracycline dose intensity and clinical outcome identifies specific chemo-resistance patterns in adult acute lymphoblastic leukemia. *Drug resistance in Leukemia and Lymphoma II*, ed. Pieters et al., Harwood Academic Publishers, Amsterdam, 1997, p. 395.

1996

Lerede T, Bassan R, Rossi A, Di Bona E, Rossi G, Pogliani EM, Motta T, Torri V, Buelli M, Comotti B, Viero P, Rambaldi A, Cortelazzo S, Rodeghiero F, Barbui T.

Therapeutic impact of adult-type acute lymphoblastic leukemia regimens in B-cell/L3 acute leukemia and advanced-stage Burkitt's lymphoma. *Haematologica*. 1996 Sep-Oct;81(5):442-9.

Bassan R, Di Bona E, Lerede T, Pogliani E, Rossi G, D'Emilio A, Buelli M, Rambaldi A, Viero P, Rodeghiero F, Barbui T. Age-adapted moderate-dose induction and flexible outpatient postremission therapy for elderly patients with acute lymphoblastic leukemia. *Leuk Lymphoma*. 1996 Jul;22(3-4):295-301.

Bassan R, Lerede T, Rambaldi A, Di Bona E, Rossi G, Pogliani E, Lambertenghi-Dellilieri G, Porcellini A, Fabris P, Barbui T. The role of anthracyclines in adult acute lymphoblastic leukaemia. *Leukemia*. 1996 Jun;10 Suppl 2:s58-61. Review.

Rambaldi A, Attuati V, Bassan R, Neonato MG, Viero P, Battista R, Di Bona E, Rossi G, Pogliani E, Ruggeri M, Amaru R, Rivolta A, Giudici G, Biondi A, Barbui T.

Molecular diagnosis and clinical relevance of t(9;22), t(4;11) and t(1 ;19) chromosome abnormalities in a consecutive group of 141 adult patients with acute lymphoblastic leukemia. *Leuk Lymphoma*. 1996 May;21(5-6):457-66.

Rambaldi A, Viero P, Bassan R, Buelli M, Rossi A, Bellavita P, Spinelli O, Amaru R, Micheletti M, Borleri G, Cortelazzo S, Comotti B, Barbui T. G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation of resistant or relapsing acute leukemias. *Leukemia*. 1996 May;10(5):860-5.

Bassan R, Amaru R, Rambaldi A, Ruggeri M, Borleri GM, Barbui T.

The natural history of monoclonal villous lymphocytosis: a chronic lymphoproliferative disorder of CD11c+ B cells. *Leuk Lymphoma*. 1996 Mar;21(1-2):181-3.

Bassan R, Lerede T, Barbui T. Strategies for the treatment of recurrent acute lymphoblastic leukemia in adults. *Haematologica*. 1996 Jan-Feb;81(1):20-36. Review.

Barbui T, Cortelazzo S, Rossi A, Viero P, Bellavita P, Buelli M, Fracassetti D, Bassan R, Comotti B, Marchioli R, Marfisi RM, Rambaldi A. Factors for rapid and sustained hematopoietic reconstitution by circulating progenitor-cell transplantation in non-Hodgkin's lymphoma. *Cancer Chemother Pharmacol*. 1996;38 Suppl:S110-4.

Bassan R, Lerede T, Rambaldi A, Barbui T. Role of anthracyclines in the treatment of adult acute lymphoblastic leukemia. *Acta Haematol*. 1996;95(3-4):188-92. Review.

Bassan R. The management of infections in patients with leukemia. *LEUKEMIA*, ed. Henderson et al. W.B. Saunders Co., Philadelphia, 1996, p. 257.

Bassan R, et al. Autotrapianto di cellule staminali circolanti o midollari nelle leucemie acute. *Progressi in Oncologia Clinica* 1996; 2: 73.

1995

Biondi A, Luciano A, Bassan R, Mininni D, Specchia G, Lanzi E, Castagna S, Cantu-Rajoldi A, Liso V, Masera G, et al. CD2 expression in acute promyelocytic leukemia is associated with microgranular morphology (FAB M3v) but not with any PML gene breakpoint. *Leukemia*. 1995 Sep;9(9):1461-6.

Bassan R, Lerede T, Barbui T. Institutional performance and dose intensity as prognostic factors in adult ALL. *Leukemia*. 1995 May;9(5):933-4.

Bassan R, Lerede T, Rambaldi A, Buelli M, Viero P, Barbui T. The use of anthracyclines in adult acute lymphoblastic leukemia. *Haematologica*. 1995 May-Jun;80(3):280-91. Review.

Bassan R, Cortelazzo S, Rambaldi A, Cornelli P, Borleri G, Bellavita P, Biondi A, Barbui T.

Autologous PBSC transplant for late onset AML after mafosfamide-purged and TBI-containing autologous BMT. *Bone Marrow Transplant*. 1995 May;15(5):791-3.

Cortelazzo S, Viero P, Bellavita P, Rossi A, Buelli M, Borleri GM, Marziali S, Bassan R, Comotti B, Rambaldi A, et al. Granulocyte colony-stimulating factor following peripheral-blood progenitor-cell transplant in non-Hodgkin's lymphoma. *J Clin Oncol*. 1995 Apr;13(4):935-41.

Bassan R, Battista R, Viero P, d'Emilio A, Buelli M, Montaldi A, Rambaldi A, Tremul L, Dini E, Barbui T. Short-term treatment for adult hypergranular and microgranular acute promyelocytic leukemia. *Leukemia*. 1995 Feb;9(2):238-43.

Bassan R, Barbui T. Remission induction therapy for adults with acute myelogenous leukemia: towards the ICE age? *Haematologica*. 1995 Jan-Feb;80(1):82-90. Review.

1994

Bassan R, Rambaldi A, Amaru R, Motta T, Barbui T. Unexpected remission of acute myeloid leukaemia after GM-CSF. *Br J Haematol.* 1994 Aug;87(4):835-8.

Barbui T, Viero P, Bassan R et al. Valutazione del rapporto costo-beneficio nell'uso clinico di G-CSF e GM-CSF. *Progressi in Ematologia Clinica* 1994; 13: 219.

1993

Bassan R, Battista R, Viero P, Pogliani E, Rossi G, Lambertenghi-Deliliers G, Rambaldi A, D'Emilio A, Buelli M, Borleri G, et al. Intensive therapy for adult acute lymphoblastic leukemia: preliminary results of the idarubicin/vincristine/L-asparaginase/prednisolone regimen. *Semin Oncol.* 1993 Dec;20(6 Suppl 8):39-46.

Bassan R, Battista R, Corneo G, Rossi G, Lambertenghi-Deliliers G, Viero P, Rambaldi A, D'Emilio A, Neonato MG, Pogliani E, et al. Idarubicin in the initial treatment of adults with acute lymphoblastic leukemia: the effect of drug schedule on outcome. *Leuk Lymphoma.* 1993 Sep;11(1-2):105-10.

Bassan R, Battista R, Montaldi A, Rambaldi A, D'Emilio A, Viero P, Boleri G, Buelli M, Dini E, Barbui T. Reinforced HEAV'D therapy for adult acute lymphoblastic leukemia: improved results and revised prognostic criteria. *Hematol Oncol.* 1993 Jul-Aug;11(4):169-77.

Rambaldi A, Bettoni S, Rossi V, Tini ML, Giudici G, Rizzo V, Bassan R, Mantovani A, Barbui T, Biondi A. Transcriptional and post-transcriptional regulation of IL-1 beta, IL-6 and TNF-alpha genes in chronic lymphocytic leukaemia. *Br J Haematol.* 1993 Feb;83(2):204-11.

Barbui T, Finazzi G, Falanga A, Battista R, Bassan R. Bleeding and thrombosis in acute lymphoblastic leukemia. *Leuk Lymphoma.* 1993;11 Suppl 2:43-7. Review.

Barbui T, Cortelazzo S, Viero P, Buelli M, Bassan R. Infection and hemorrhage in elderly acute myeloblastic leukemia and primary myelodysplasia. *Hematol Oncol.* 1993;11 Suppl 1:15-8.

Barbui T, Finazzi G, Falanga A, Battista R, Bassan R. Emorragie e trombosi nelle leucemie acute. *Progressi in Ematologia Clinica* 1993; 12: 187.

1992

Bassan R et al. Patologia proliferativa cronica dei linfociti granulati. *Progressi in Ematologia Clinica* 1992; 11: 105.

Bassan R, Buelli M, Viero P, Minotti C, Barbui T. The management of acute myelogenous leukemia in the elderly: ten-year experience in 118 patients. *Hematol Oncol.* 1992 Sep-Oct;10(5):251-60.

Bassan R, Cornelli PE, Battista R, Terzi F, Buelli M, Rambaldi A, Viero P, D'Emilio A, Dini E, Barbui T. Intensive retreatment of adults and children with acute lymphoblastic leukemia. *Hematol Oncol.* 1992 Mar-Apr;10(2):105-10. Specchia G, Liso V, Capalbo S, Fazioli F, Bettoni S, Bassan R, Viero P, Barbui T, Rambaldi A. Constitutive expression of IL-1 beta, M-CSF and c-fms during the myeloid blastic phase of chronic myelogenous leukaemia. *Br J Haematol.* 1992 Mar;80(3):310-6.

Bassan R, Biondi A, Benvestito S, Tini ML, Abbate M, Viero P, Barbui T, Rambaldi A. Acute undifferentiated leukemia with CD7+ and CD13+ immunophenotype. Lack of molecular lineage commitment and association with poor prognostic features. *Cancer.* 1992 Jan 15;69(2):396-404.

Maserati E, Casali M, Pasquali F, Locatelli F, Giani S, Prete L, Zecca M, Invernizzi R, Bassan R. Translocation (8;21) in two cases of refractory anemia with excess of blasts in transformation. *Cancer Genet Cytogenet.* 1992 Jan;58(1):76-8. Review.

Rohatiner AZ, Battista R, Bassan R, Love S, Oza AM, Whelan JS, Lim J, Buelli M, Viero P, D'Emilio A, et al. Short term therapy (STT) for acute myelogenous leukaemia (AML). *Leukemia.* 1992;6 Suppl 2:85-8.

Bassan R, Battista R, Rohatiner AZ, Love S, Carter M, Buelli M, Viero P, D'Emilio A, MacCallum P, Amess J, et al. Treatment of adult acute lymphoblastic leukaemia (ALL) over a 16 year period. *Leukemia.* 1992;6 Suppl 2:186-90.

1991

Bassan R, Neonato MG, Abbate M, Motta T, Barbui T, Rambaldi A. Monoclonal lymphocytosis with villous lymphocytes: a chronic lymphoproliferative disease of CD11c+ B-cells. *Leukemia.* 1991 Sep;5(9):799-806.

Bandini G, Zuffa E, Rosti G, Battista R, D'Emilio E, Leoni F, Ciolli S, Barbui T, Bassan R, Todeschini G, et al. Long-term outcome of adults with acute myelogenous leukaemia: results of a prospective, randomized study of chemotherapy with a minimal follow-up of 7 years. *Br J Haematol.* 1991 Apr;77(4):486-90.

Battista R, Bassan R, D'Emilio A, Dragone P, Viero P, Dini E, Barbui T. Short-term remission induction and consolidation therapy for adult acute myelogenous leukemia. *Hematol Oncol*. 1991 Jan-Feb;9(1):43-52.

Bassan R, Battista R, D'Emilio A, Viero P, Dragone P, Dini E, Barbui T. Long-term results of the HEAVD protocol for adult acute lymphoblastic leukaemia. *Eur J Cancer*. 1991;27(4):441-7.

Carella A ... Bassan R et al. Nine years' experience with ABMT in 128 patients with Hodgkin's disease: an Italian study group report. *Leukemia* 1991; 5 (suppl 1): 68.

T Barbui, Bassan R. Malattie neoplastiche del sangue. *Diagnosi e terapia medica pratica*. Ed C Zanussi, UTET 1991: 441.

1990

Rambaldi A, Terao M, Bettoni S, Tini ML, Bassan R, Barbui T, Garattini E. Expression of leukocyte alkaline phosphatase gene in normal and leukemic cells: regulation of the transcript by granulocyte colony-stimulating factor. *Blood*. 1990 Dec 15;76(12):2565-71.

Bassan R, Rambaldi A, Abbate M, Biondi A, Allavena P, Barbui T, Bertani T. Association of NK-cell lymphoproliferative disease and nephrotic syndrome. *Am J Clin Pathol*. 1990 Sep;94(3):334-8.

Rohatiner AZ, Bassan R, Battista R, Barnett MJ, Gregory W, Lim J, Amess J, Oza A, Barbui T, Horton M, et al. High dose cytosine arabinoside in the initial treatment of adults with acute lymphoblastic leukaemia. *Br J Cancer*. 1990 Sep;62(3):454-8.

Donati MB, Falanga A, Consonni R, Alessio MG, Bassan R, Buelli M, Borin L, Catani L, Pogliani E, Gugliotta L, et al. Cancer procoagulant in acute non lymphoid leukemia: relationship of enzyme detection to disease activity. *Thromb Haemost*. 1990 Aug 13;64(1):11-6.

Alessio MG, Falanga A, Consonni R, Bassan R, Minetti B, Donati MB, Barbui T. Cancer procoagulant in acute lymphoblastic leukemia. *Eur J Haematol*. 1990 Aug;45(2):78-81.

Rohatiner AZ, Bassan R, Battista R, Barnett MJ, Gregory W, Lim J, Amess J, Oza A, Barbui T, Horton M, et al. Intensive chemotherapy for acute lymphoblastic leukaemia in adults. *Haematol Blood Transfus*. 1990;33:413-8.

Allavena P, Biondi A, Rossi V, Rambaldi A, Bassan R et al. Expression of the T cell receptor delta gene in normal and leukemic natural killer cells. *Natural killer cell workshop*. Ed. Schmidt RE, Karger 1990: 1.

Barbui T, Viero P, Rambaldi A, Bassan R. Il linfoma di Burkitt. *Progressi in Ematologia Clinica* 1990; 9: 181.

1989

Bassan R, Rambaldi A, Viero P, Borleri G, Barbui T. Integrated use of morphology, cytochemistry, and immune marker analysis to identify acute leukaemia subtypes. *Haematologica*. 1989 Sep-Oct;74(5):487-90.

Biondi A, Allavena P, Rossi V, Bassan R, Barbui T, Champagne E, Mak TW, Minden MD, Rambaldi A, Mantovani A. T cell receptor delta gene organization and expression in normal and leukemic natural killer cells. *J Immunol*. 1989 Aug 1;143(3):1009-14.

Rambaldi A, Terao M, Bettoni S, Bassan R, Battista R, Barbui T, Garattini E. Differences in the expression of alkaline phosphatase mRNA in chronic myelogenous leukemia and paroxysmal nocturnal hemoglobinuria polymorphonuclear leukocytes. *Blood*. 1989 Apr;73(5):1113-5.

Biondi A, Rossi V, Bassan R, Barbui T, Bettoni S, Sironi M, Mantovani A, Rambaldi A. Constitutive expression of the interleukin-6 gene in chronic lymphocytic leukemia. *Blood*. 1989 Apr;73(5):1279-84.

Bregni M, Siena S, Neri A, Bassan R, Barbui T, Delia D, Bonadonna G, Dalla Favera R, Gianni AM. Minimal residual disease in acute lymphoblastic leukemia detected by immune selection and gene rearrangement analysis. *J Clin Oncol*. 1989 Mar;7(3):338-43.

Bassan R, Pronesti M, Buzzetti M, Allavena P, Rambaldi A, Mantovani A, Barbui T. Autoimmunity and B-cell dysfunction in chronic proliferative disorders of large granular lymphocytes/natural killer cells. *Cancer*. 1989 Jan 1;63(1):90-5.

Bassan R et al. The chronic proliferative disease of large granular lymphocytes. *Haematologica* 1989, 74:85.

Bassan R et al. Autoimmunity and second malignancy in large granular lymphocytic leukaemia. *Bone Marrow Transplant* 1989; 4 (suppl 1): 149.

Carella AM, ... Bassan R et al. Italian experience with autologous bone marrow transplantation in 104 advanced Hodgkin's lymphoma patients. *Bone Marrow Transplant* 1989; 4 (suppl 4): 113.



1988

Bassan R, Rambaldi A, Allavena P, Abbate M, Marini B, Barbui T. Association of large granular lymphocyte/natural killer cell proliferative disease and second hematologic malignancy. *Am J Hematol.* 1988 Oct;29(2):85-93.

Marini B, Bassan R, Barbui T. Therapeutic efficacy of danazol in myelodysplastic syndromes. *Eur J Cancer Clin Oncol.* 1988 Sep;24(9):1481-9.

Bassan R, Buzzetti M, Marini B, Rambaldi A, Allavena P, Barbui T. Investigation of chronic lymphocytosis in adults. *Am J Clin Pathol.* 1988 Jun;89(6):783-7.

Rohatiner AZ, Gregory WM, Bassan R, Barnett MJ, Waxman J, Richards MA, Ganesan TS, Tucker J, Malik ST, Biruls R, et al. Short-term therapy for acute myelogenous leukemia. *J Clin Oncol.* 1988 Feb;6(2):218-26.

Bassan R et al. Linfocitosi cronica dell'adulto : studio di 21 casi. *NAM* 1988; 4: 536.

1987

Lister TA, Rohatiner AZ, Bassan R, Gregory W, Willis L, Barnett MJ, Waxman J, Richards MA, Ganesan TS, Tucker J, et al. Conventional dose cytosine arabinoside in combination chemotherapy for acute myelogenous leukemia.

*Semin Oncol.* 1987 Jun;14(2 Suppl 1):53-4.

Bassan R, Battista R, Comotti B, Minetti B, Chisesi T, Dini E, Barbui T. Treatment of the lymphoid blast crisis of chronic myeloid leukemia. *Eur J Cancer Clin Oncol.* 1987 May;23(5):513-5.

Bassan R, Pronesti M, Buzzetti M, Viero P, Minetti B, Comotti B, Buelli M, Barbui T.

Surface immunoglobulin intensity and p67 (CD5) antigen expression define different forms of B-cell chronic lymphocytic leukaemia. *Haematologica.* 1987 May-Jun;72(3):221-5.

Bassan R, Marini B, Allavena P, Pirelli A, Barbui T. RAEB in a patient with chronic granulated T-lymphocytosis. *Br J Haematol.* 1987 Apr;65(4):503-4.

Comotti B, Bassan R, Buzzetti M, Finazzi G, Barbui T. Multiple myeloma in a pair of twins. *Br J Haematol.* 1987 Jan;65(1):123-4.

Barnett MJ, Rohatiner AZ, Kingston JE, Adams KE, Batten EL, Bassan R, Thorpe PE, Horton MA, Malpas JS, Lister TA. In vitro treatment of bone marrow from patients with T-cell acute lymphoblastic leukemia and non-Hodgkin's lymphoma using the immunotoxin WT1-ricin A. *Haematol Blood Transfus.* 1987;31:57-8.

Bassan R, Rohatiner AZ, Gregory W, Amess J, Biruls R, Barnett MJ, Lister TA.

The treatment of acute myelogenous leukemia. *Haematol Blood Transfus.* 1987;31:35-6.

Pirelli A, P. Allavena, S. Rossini, M. Di Bello, A. Rambaldi, Bassan R et al; Immunological and genotypic analysis of 15 patients with a proliferative disorders of large granular lymphocytes and granulocytopenia. *Adv Biosci* 1987, 66:641.

1986

Bassan R, Introna M, Rambaldi A, Viero P, Chisesi T, Mantovani A, Barbui T. Large granular lymphocyte/natural killer cell proliferative disease: clinical and laboratory heterogeneity.

*Scand J Haematol.* 1986 Aug;37(2):91-6.

Viero P, Cortelazzo S, Buelli M, Comotti B, Minetti B, Bassan R, Barbui T. Thrombotic thrombocytopenic purpura and high-dose immunoglobulin treatment. *Ann Intern Med.* 1986 Feb;104(2):282.

Rambaldi A, Rossi V, Allavena P, Introna M, Landolfo S, Bassan R, Barbui T, Mantovani A. Lymphokine production in T gamma lymphoproliferative disorders. *Scand J Immunol.* 1986 Feb;23(2):183-8.

Allavena P, Introna M, Rambaldi A, Zanaboni F, Rossini S, Villa A, Bassan R, Barbui T, Mantovani A. Induction of cytotoxicity by interleukin-2 in T gamma-lymphoproliferative disorders. *Int J Cancer.* 1986 Jan 15;37(1):27-33.

Rambaldi A, Allavena P, Pirelli A, Di Bello M, Rossini S, Bassan R, Barbui T, Pelicci PG, Dalla Favera R, Mantovani A. Immunological and genotypic analysis of human T gamma-lymphoproliferative disorders. *Ric Clin Lab.* 1986 Jan-Mar;16(1):29-35.

Bottazzi B, Rambaldi A, Introna M, Merendino A, Piovella F, Bassan R, Viero P, Barbui T, Mantovani A. Migratory capacity of large granular lymphocytes from T-gamma-lymphoproliferative disorders. *Nat Immun Cell Growth Regul.* 1986;5(1):19-27.

Minetti B, Montanelli A, Comotti B, Bassan R et al. La malattia di Gaucher: straordinaria incidenza in provincia di Bergamo. *NAM* 1986; 2: 191.



Battista R, D'Emilio A, Comotti B, Bassan R et al. High dose cytosine arabinoside in the treatment of resistant acute leukemia. *New Trends Ther. Leuk. Lymph.* 1986; 1: 9.

Barbui T, Comotti B, Buelli M, Minetti B, Cortelazzo S, Viero P, Bassan R. VP-16 and high dose cytosine arabinoside in the treatment of resistant Hodgkin's disease. *New Trends Ther. Leuk. Lymph.* 1986; 1: 39.

1985

Rambaldi A, Pelicci PG, Allavena P, Knowles DM 2nd, Rossini S, Bassan R, Barbui T, Dalla-Favera R, Mantovani A. T cell receptor beta chain gene rearrangements in lymphoproliferative disorders of large granular lymphocytes/natural killer cells. *J Exp Med.* 1985 Dec 1;162(6):2156-62.

Bassan R, Montanelli A, Barbui T. Interaction between a serum factor and T lymphocytes in Gaucher disease. *Am J Hematol.* 1985 Apr;18(4):381-4.

Buelli M, Cortelazzo S, Viero P, Minetti B, Comotti B, Bassan R, Barbui T. Danazol for the treatment of idiopathic thrombocytopenic purpura. *Acta Haematol.* 1985;74(2):97-8.

Barbui T, Bassan R, Chisesi T, Battista R, Cortelazzo S, Rodeghiero F, Capnist G, D'Emilio A, Viero P, Dini E. Treatment of acute lymphoblastic leukemia in adults. *Hematol Oncol.* 1985 Jan-Mar;3(1):49-53.

1984

Barbui T, Bassan R, Viero P, Minetti B, Comotti B, Buelli M. Pure white cell aplasia treated by high dose intravenous immunoglobulin. *Br J Haematol.* 1984 Nov;58(3):554-5.

Bassan R, Comotti B, Minetti B, Viero P, Barbui T. Concurrent multiple myeloma and chronic lymphocytic leukemia. *Am J Clin Pathol.* 1984 Nov;82(5):624-7.

Bassan R, Viero P, Minetti B, Comotti B, Barbui T. Myelokathexis: a rare form of chronic benign granulocytopenia. *Br J Haematol.* 1984 Sep;58(1):115-7.

Rambaldi A, allavena P, Introna M, Zanaboni F, Ropssi V, Bassan R et al. T-gamma lymphoproliferative disorders: studies on cytotoxic activity, membrane antigen expression and lymphokine production. *New trends in experimental hematology.* Ed. C Peschle, C Rizzoli, ARES Serono Symposia, 1984, p 499.

Minetti B, Bellavista P, Pronesti RM, Comotti B, Bassan R et al. Incrementi piastrinici post-trasfusionali nelle leucemie acute. *La T. d. S.* 1984; 29: 429.

1983

Barbui T, Cortelazzo S, Viero P, Bassan R, Dini E, Semeraro N. Thrombohaemorrhagic complications in 101 cases of myeloproliferative disorders: relationship to platelet number and function. *Eur J Cancer Clin Oncol.* 1983 Nov;19(11):1593-9.

Barbui T, Bassan R, Viero P, Cortelazzo S, Dini E. Platelet function after busulphan in chronic myeloproliferative disorders. *Haematologica.* 1983 Jul-Aug;68(4):469-77.

1982

Viero P, Cortelazzo S, Bassan R, Barbui T. Effect of aspirin on platelet 5-hydroxytryptamine and beta-thromboglobulin plasma levels in patients with myeloproliferative diseases. *Thromb Haemost.* 1982 Oct 29;48(2):125-6.

Barbui T, Bassan R, Chisesi T, Battista R, Cortelazzo S, Rodeghiero F, Capnist G, Viero P, D'Emilio A, Dini E. Retrospective analysis of treatment of acute myeloblastic leukemia in patients more than 55 years old. *Acta Haematol.* 1982;67(3):170-4.

Cortelazzo S, Viero P, Bassan R et al. Spectrum of platelet aggregation abnormalities in myeloproliferative diseases. *LA RICERCA CLIN LAB* 1982, 11:35.

1980

Cortelazzo S, Barbui T, Bassan R, Dini E. Abnormal aggregation and increased size of platelets in myeloproliferative disorders. *Thromb Haemost.* 1980 Jun 18;43(2):127-30.

1979

Cortelazzo S, Barbui T, Viero P, Bassan R, Dini E, Ferro Milone F. Platelet malonyldialdehyde and spontaneous aggregation during ischaemic attacks of patients with polycythaemia vera. *Thromb Haemost.* 1979 Dec 21;42(4):1344-6.

## Projects

### Memberships

#### Scientific Societies:

1980 Societa Italiana di Ematologia

2002 European Leukemia Network (ELN), leading participant del WP6 (EWALL, European Group on Adult Lymphoblastic leukemia)

2011 European Hematology Association

#### Consultancy:

1992 Hematology Consultant, USSL 11 Ponte S. Pietro (BG)

2001 Hematology Consultant, Ospedale di Seriate (BG)

2005-2011: Hematology Consultant, Ospedale di Romano L.do (BG)

#### Editorial Board:

1998: Haematologica

2004: Clinical Editor di State-of-the-Art (START) in Oncology, Leukemia section.

2010: The Journal of Clinical Oncology

2012: Drugs and Cell Therapies in Hematology (section editor)

2012: Leukemia Research and Treatment

#### Reviewer:

Haematologica/The Haematology Journal,

Acta Haematologica,

Cancer,

Blood,

Leukemia & Lymphoma,

Hematological Oncology,

International Journal of Hematology,

Annals of Hematology,

Journal of Clinical Oncology,

European Journal of Cancer,

Bone Marrow Transplantation,

Annals of the New York Academy of Science,

BMC Pediatrics,

European Journal of Haematology,

BMC Cancer

Chinese Journal of Cancer Research,

Molecular Diagnosis and Therapy,

Pediatrics,

The Lancet Oncology,

Jacobs Journal of Clinical Case Reports,

Pediatrics,

OncoTargets and Therapy,

Expert Reviews of Anticancer Therapy,

Journal of Leukemia,

Blood Reviews,

Canadian Journal of Physiology and Pharmacology,

Scientific Reports,

Oncotarget,

Journal of Spine & Neurosurgery,

Malaysian Journal of Pathology,

Mediterranean Journal of Hematology and Infectious Diseases

Translational Cancer Research,

Clinics in Oncology,

Journal of Pediatric Hematology and Oncology,

Expert Reviews of Hematology,  
The Lancet Haematology,  
Case Reports in Oncological Medicine  
HSOA Journal of Clinical Studies & Medical Case Reports  
International Journal of STD and AIDS  
JSM Anatomy & Physiology  
BMJ Case Reports  
JCO Precision Oncology  
HemaSphere  
Cancer Medicine  
Case Reports in Medicine  
Blood Advances  
Therapeutic Advances in Hematology  
Clinical Case Reports  
Cancers  
International Journal of Molecular Sciences  
American Journal of Hematology  
International Journal of Molecular Sciences  
Immunobiology  
Frontiers in Oncology  
Medicina

[Other Relevant Information](#)